Sanofi SA, a global healthcare leader headquartered in Switzerland (CH), is renowned for its innovative contributions to the pharmaceutical industry. Founded in 2004 through the merger of Sanofi-Synthélabo and Aventis, the company has established a strong presence in key operational regions, including Europe, North America, and Asia. Specialising in prescription medicines, vaccines, and consumer healthcare products, Sanofi is committed to addressing complex health challenges. Its core offerings include diabetes care solutions, rare disease treatments, and vaccines, distinguished by their cutting-edge research and development. With a robust market position, Sanofi has achieved notable milestones, such as being a top player in the global vaccine market and consistently ranking among the leading pharmaceutical companies worldwide.
How does Sanofi SA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Sanofi SA's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sanofi SA, headquartered in Switzerland (CH), currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of Sanofi, the company is engaged in various climate initiatives, although no specific reduction targets or achievements have been documented. Sanofi has committed to several industry-standard climate initiatives, including the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded from the parent organization. However, detailed emissions data and specific reduction targets have not been disclosed. In the absence of concrete emissions figures, it is important to note that Sanofi is actively participating in climate commitments aimed at reducing its carbon footprint and enhancing sustainability practices within the pharmaceutical industry.
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Sanofi SA's Scope 3 emissions, which decreased by 5% last year and increased by approximately 40% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 69% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sanofi SA has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.